Through several mechanisms, most antidepressants cause potentiation of the neurotransmitter actions of NE, 5-HT, or both.
Most of the TCAs inhibit the reuptake of norepinephrine, though not dopamine, and as a result, they show some efficacy in remedying the disorder.
The adverse effects of TCAs, which result largely from their anticholinergic and antihistaminic properties, include the following: Sedation, confusion, dry mouth, orthostasis, constipation, urinary retention, sexual dysfunction and weight gain.
Some tricyclic antidepressants are more likely to cause side effects that affect safety, such as Disorientation or confusion, particularly in older people when the dosage is too high. Increased or irregular heart rate. More frequent seizures in people who have seizures.
Mirtazapine is part of the tetracyclic antidepressants (TeCA) group that works by exerting antagonist effects on the central presynaptic alpha-2-adrenergic receptors, which causes an increased release of serotonin and norepinephrine.
Venlafaxine works by increasing serotonin levels, norepinephrine, and dopamine in the brain by blocking transport proteins and stopping their reuptake at the presynaptic terminal.
Agomelatine has been shown to block 5-HT2C receptors within corticolimbic structures in the hippocampus. Hyperactivity of the 5-HT2C receptors may contribute to the symptoms of MDD and agomelatine induced 5-HT2C antagonism has been shown to increase the release of dopamine and norepinephrine in the frontal cortex.